ECS Botanics plans to introduce two 2g all-in-one vape products under its OzSun brand in mid-August 2026, expanding its higher-margin B2C portfolio with a capital-efficient supply model.
- Two 2g all-in-one rosin blend vapes launching mid-August
- Supplied via consignment by Canadian GMP-licensed manufacturer Ichor
- Larger 2g format aims to offer better value than 1g market standard
- Expected gross margins align with ECS’s AVANI branded products
- Vape category well-established in North America supports product rationale
ECS Targets Australian Vape Market with Larger Format
ECS Botanics Holdings Ltd (ASX:ECS) is set to expand its OzSun portfolio with the launch of two 2g all-in-one rosin blend vape products scheduled for mid-August 2026. These vapes combine reservoir, battery, heating core, and mouthpiece into a rechargeable, inhalation-activated device, removing the need for separate batteries common in traditional 1g vape cartridges. The move introduces a larger format to the Australian medicinal cannabis vape category, which is predominantly dominated by 1g products, aiming to provide competitive value per gram.
Capital-Efficient Supply via Canadian Partner
The new OzSun vapes will be supplied by Canadian GMP-licensed manufacturer Ichor Inc under a consignment agreement, a model that limits upfront capital expenditure by making product costs payable as inventory sells. ECS expects gross margins from the range to be broadly consistent with its higher-margin AVANI branded products, reflecting a disciplined extension of its branded B2C portfolio without material capital outlay.
Formulations and Product Features
The initial launch includes two tri-blend formulations aligned with OzSun’s Day and Night product architecture, each combining three cannabinoids: the Day product includes CBG, while the Night product contains CBN. Both use rosin and distillate blends with native cannabis terpenes, manufactured in Canada and imported with all necessary Australian approvals. The integrated device uses a proprietary ceramic heating core and USB-C rechargeable battery, designed for convenience and ease of use.
Market Validation from North America
While ECS does not present North American data as a direct forecast for Australia, the company highlights that vape products are the second-largest cannabis category by sales in the US and third-largest in Canada. BDSA data shows vapes accounted for approximately 26% of US legal cannabis retail sales in the 12 months to May 2026, generating around US$8 billion in revenue. Notably, disposable vape sales increased by 41%, with larger 2g formats identified as key growth drivers. This international context supports ECS’s rationale for introducing a larger-format vape product domestically.
Launch Strategy and Outlook
The OzSun all-in-one vape range will roll out through ECS’s existing Australian medicinal cannabis distribution channels, supported by Medical Science Liaison engagement with healthcare professionals. The company will monitor initial sales and uptake before deciding on the timing and scale of further orders. ECS anticipates the range will contribute to continued growth and diversification of its branded B2C portfolio, with further updates to follow if sales performance or product expansion become material.
Bottom Line?
ECS’s launch of a larger-format, integrated vape product leverages a capital-light supply model to target growth in Australia’s medicinal cannabis market, but early sales will be pivotal to scaling the range.
Questions in the middle?
- How will Australian consumers respond to the larger 2g vape format compared to the prevalent 1g standard?
- Will the consignment supply model with Ichor support sustainable scaling if demand exceeds initial expectations?
- Could regulatory changes impact the uptake or formulation of medicinal cannabis vape products in Australia?